Profile data is unavailable for this security.
About the company
Hainan Huluwa Pharmaceutical Group Co Ltd is a China-based company principally involved in the research and development, manufacturing and sales of Chinese patent medicines and chemical drugs. Its products are used in the pharmaceutical fields of respiratory system, digestive system, systemic anti-infection, including pediatric lung heat cough asthma granules, bromhexine hydrochloride for injection, compound Banlangen granules, Keke tablets, omeprazole enteric-coated capsules , Changyanning (capsules and granules), omeprazole sodium for injection, sodium diisopropylamine dichloroacetate for injection and cefixime dispersible tablets, among others. The Company also provides gynecological medicine, cardiovascular system medicine and neurological system medicine preparation products. The Company operates its businesses in the domestic market.
- Revenue in CNY (TTM)1.81bn
- Net income in CNY94.97m
- Incorporated2005
- Employees2.47k
- LocationHainan Huluwa Pharmaceutical Group Co LtdNo. 30, Andu 1st Road, Xiuying DistrictHAIKOU 570311ChinaCHN
- Phone+86 89 868634767
- Fax+86 89 868631245
- Websitehttp://www.huluwayaoye.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hunan Warrant Pharmaceutical Co Ltd | 1.45bn | 222.11m | 3.97bn | 1.16k | 17.86 | 2.22 | -- | 2.74 | 2.37 | 2.37 | 15.44 | 19.01 | 0.6713 | 1.50 | 8.93 | 1,246,491.00 | 9.31 | 11.21 | 11.21 | 14.05 | 64.09 | 69.00 | 13.88 | 13.96 | 3.02 | -- | 0.0252 | 8.05 | 10.84 | 18.50 | 15.60 | 19.02 | 24.49 | -- |
| Beijing Konruns Pharmaceutical Co Ltd | 954.14m | 166.44m | 3.99bn | 447.00 | 23.53 | 1.26 | -- | 4.18 | 1.06 | 1.06 | 6.05 | 19.78 | 0.2548 | 2.50 | 3.73 | 2,134,547.00 | 5.46 | 5.43 | 6.39 | 6.24 | 88.29 | 89.93 | 21.44 | 20.76 | 3.08 | -- | 0.0486 | 21.53 | 6.15 | -2.08 | 48.24 | -10.63 | 43.05 | -9.71 |
| Shanghai Hile Bio-Technology Co Ltd | 239.79m | 44.92m | 4.04bn | 295.00 | 91.78 | 3.23 | -- | 16.85 | 0.0669 | 0.0669 | 0.3664 | 1.90 | 0.154 | 1.06 | 2.40 | 812,857.50 | 2.06 | 1.73 | 2.56 | 2.47 | 45.19 | 50.44 | 13.37 | 10.37 | 1.16 | -- | 0.0562 | 23.89 | -19.76 | -1.11 | -48.30 | 24.17 | -41.32 | 23.47 |
| Hainan Huluwa Pharmaceutical Grop Co Ltd | 1.81bn | 94.97m | 4.07bn | 2.47k | 42.89 | 3.54 | -- | 2.25 | 0.2374 | 0.2374 | 4.52 | 2.87 | 0.6721 | 2.88 | 3.81 | 732,708.90 | 3.80 | 5.81 | 6.29 | 9.78 | 50.33 | 58.01 | 5.66 | 7.03 | 0.8245 | 7.04 | 0.5246 | 21.74 | 25.75 | 14.13 | 24.29 | 1.16 | 46.37 | -- |
| Yabao Pharmaceutical Group Co Ltd | 2.88bn | 204.43m | 4.14bn | 4.14k | 20.88 | 1.42 | -- | 1.44 | 0.2754 | 0.2754 | 3.81 | 4.05 | 0.7193 | 2.98 | 6.79 | 695,432.10 | 4.52 | 2.82 | 5.90 | 3.97 | 56.00 | 59.20 | 6.29 | 4.19 | 1.62 | 47.13 | 0.0675 | 43.74 | 7.05 | -0.0572 | 90.71 | -6.10 | 7.98 | -9.71 |
| Zhejiang Starry Pharmaceutical Co Ltd | 2.27bn | 46.95m | 4.16bn | 1.85k | 69.37 | 1.84 | -- | 1.83 | 0.1368 | 0.1368 | 6.63 | 5.15 | 0.4179 | 1.98 | 5.09 | 1,231,642.00 | 0.8789 | 3.30 | 1.80 | 5.97 | 23.86 | 32.35 | 2.10 | 8.21 | 0.4121 | 1.44 | 0.6405 | 53.08 | 3.04 | 19.78 | 158.32 | -13.94 | 10.39 | -- |
| Shanghai Haixin Group Co Ltd | 1.11bn | 171.70m | 4.16bn | 760.00 | 33.05 | 1.44 | -- | 3.76 | 0.1422 | 0.1422 | 0.9185 | 3.27 | 0.2246 | 7.19 | 9.32 | 1,458,849.00 | 4.05 | 2.68 | 4.57 | 3.06 | 46.37 | 44.55 | 18.02 | 11.17 | 2.83 | -- | 0.0089 | 36.10 | -17.88 | 1.48 | 1.20 | 4.19 | -10.27 | 13.18 |
Data as of Jul 05 2024. Currency figures normalised to Hainan Huluwa Pharmaceutical Group Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
0.20%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 490.70k | 0.12% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 174.53k | 0.04% |
| Shanghai Guotai Junan Securities Assets Management Co., Ltd.as of 31 Dec 2023 | 68.30k | 0.02% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 31 Dec 2023 | 25.30k | 0.01% |
| Yinhua Fund Management Co., Ltd.as of 31 Dec 2023 | 16.30k | 0.00% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 12.20k | 0.00% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 4.80k | 0.00% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 2.90k | 0.00% |
| Guotai Asset Management Co., Ltd.as of 31 Dec 2023 | 600.00 | 0.00% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
